Active Filter(s):
Details:
This is a Phase 2 multi-center, randomized, double-blind, placebo-controlled study that will evaluate the safety and prophylactic efficacy of AdMSCs against COVID-19.
Lead Product(s): Autologous adipose-derived stem cells
Therapeutic Area: Infections and Infectious Diseases Product Name: AdMSCs
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020